Variables affecting the quantitation of CD22 in neoplastic B cells

Abstract

Background: Quantitative flow cytometry (QFCM) is being applied in the clinical flow cytometry laboratory for diagnosis, prognosis, and assessment of patients receiving antibody-based therapy. ABC values and the effect of technical variables on CD22 quantitation in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), follicular lymphoma (FCL), hairy cell leukemia (HCL) and normal B cells were studied.Methods: The QuantiBrite System V R was used to determine the level of CD22 expression (mean antibody bound per cell, ABC) by malignant and normal B cells. The intra-assay variability, number of cells required for precision, effect of delayed processing as well as shipment of peripheral blood specimens (delayed processing and exposure to noncontrolled environments), and the effect of paraformaldehyde fixation on assay results were studied.Results: The QuantiBRITE method of measuring CD22 ABC is precise (median CV 1.6%, 95% confidence interval, 1.2-2.3%) but a threshold of 250 malignant cells is required for reliable CD22 ABC values. Delayed processing and overnight shipment of specimens resulted in significantly different ABC values whereas fixation for up to 12 h had no significant effect. ABC measurements determined that CD22 expression is lower than normal in ALL, CLL, FCL, and MCL but higher than normal in HCL.Conclusions: CD22 expression was atypical in the hematolymphoid malignancies studied and may have diagnostic utility. Technical variables such as cell number analyzed and delayed processing or overnight shipment of specimens impact significantly on the measurement of antigen expression by QFCM in the clinical laboratory. Published

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

“…Antigen-site density was quantified by determining the anti-CD22 antibody-binding capacity per cell using the QuantiBRITE system for fluorescence quantitation (BD Biosciences, San Jose, CA) as previously described. 13 Determination of minimal residual disease (MRD) in patients who achieved CR was performed by flow cytometry on bone marrow aspirate samples using standard methodology. 14 …”

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

“…As a drawback, this method may introduce stability issues with specific antibody-fluorochrome conjugates (e.g., APC-tandem dyes) if cell fixation steps are not introduced after the staining (15). The entire specimen can be gently pre-lysed by incubating with 155 mM ammonium chloride, 10 mM potassium bicarbonate, and 0.2 mM EDTA (freshly prepared/commercially available) for 10 min at room temperature at a ratio of 1:9 (Volume of sample:volume of lysing solution; (16). The cells are then pelleted at 500g, washed with PBS and reconstituted at an appropriately high concentration to deliver 3-10 million cells in 100-200 lL per tube.…”

Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development

“…Furthermore, the receptor density is generally useful for mechanistic PK/PD models and, in absence of measurement, this parameter is estimated. Efforts to move from relative to absolute receptor quantification (= receptor density) have typically focused on the use of highly characterized detection reagents and fluorescent calibration beads 57, 58.…”